[Featured Stock] Rekembe Expected to Expand Sales... PeopleBio Up Over 7%

The stock price of PeopleBio, expected to benefit from the domestic launch of the Alzheimer's treatment drug Rekembi, is showing strong performance.

As of 9:19 AM on the 28th, PeopleBio was trading at 3,920 KRW, up 260 KRW (7.10%) from the previous trading day.

On the same day, Kim Juhyung, a researcher at Growth Research, stated, "Rekembi is scheduled to be launched domestically next month," adding, "Accordingly, the demand for PeopleBio's early Alzheimer's diagnosis blood test kit 'AlzOn' is expected to increase."

He also said, "This year, PeopleBio started providing AlzOn testing services to the Korea Health Screening Association, the top health screening center in Korea, and signed supply contracts for AlzOn Plus with several medical institutions," adding, "Sales expansion is expected through entry into and expansion of the overseas blood diagnostic market as well as domestic markets."